Staidson (beijing) Biopharmaceuticals Co., Ltd
Clinical trials sponsored by Staidson (beijing) Biopharmaceuticals Co., Ltd, explained in plain language.
-
New drug aims to tame rare blood vessel disease
Disease control Recruiting nowThis Phase 3 trial is testing whether adding BDB-001 to standard treatments (cyclophosphamide, azathioprine, rituximab, or prednisone) helps more people with ANCA-associated vasculitis achieve remission. The study plans to enroll 300 adults with active GPA or MPA. Participants wi…
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New eye drops aim to heal corneal damage and restore sensation
Disease control Recruiting nowThis study tests an experimental eye drop called STSP-0902 for people with neurotrophic keratitis, a rare condition where the cornea loses sensation and can develop ulcers. The trial will enroll 48 adults with moderate to severe disease. Participants will receive either the activ…
Phase: PHASE2 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug aims to save lives in severe respiratory failure
Disease control Recruiting nowThis Phase 3 trial tests an experimental drug called STSA-1002 in 406 adults with acute respiratory distress syndrome (ARDS) caused by a viral infection. Participants receive either the drug or a placebo added to standard care. The main goal is to see if the drug lowers the chanc…
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New injection aims to boost sperm count – first human safety tests underway
Symptom relief Recruiting nowThis early-stage study is testing a new drug called STSP-0902 to see if it is safe for men. It includes healthy volunteers and men with low sperm count or low sperm movement. The main goal is to check for side effects and how the drug moves through the body. This is a first step …
Phase: PHASE1 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC